论文部分内容阅读
目的观察甲状腺功能亢进性肝损害的治疗效果。方法选择2010年4月—2013年4月在我院治疗的甲状腺功能亢进性肝损害的患者60例,随机分为对照组和观察组各30例。对照组仅给予常规保肝治疗。观察组在常规保肝治疗的基础上给予131I进行治疗,同时患者口服甲硫咪唑、丙基硫氧嘧啶进行治疗并根据患者肝功能及甲状腺功能的状况进行调整。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果治疗后,对照组TB、DB、FT3、FT4、TT3分别为(51.3±1.9)、(26.5±1.2)μmol/L、(7.92±1.34)pg/ml、(5.08±1.27)、(6.78±0.97)ng/ml,观察组分别为(21.1±1.5)、(8.3±0.8)μmol/L、(4.14±1.21)pg/ml、(2.19±0.82)、(2.31±0.91)ng/ml,两组比较差异均有统计学意义(均P<0.05)。结论甲状腺功能亢进性肝损害在常规的保肝治疗基础上需进行抗甲状腺治疗,患者预后良好,痛苦减轻,值得临床推广。
Objective To observe the therapeutic effect of hyperthyroidism with liver damage. Methods Sixty patients with hyperthyroidism and liver damage who were treated in our hospital from April 2010 to April 2013 were randomly divided into control group and observation group of 30 cases. Control group only given conventional liver protection. The observation group was treated with 131I on the basis of conventional hepatoprotective therapy. At the same time, the patients were treated with methimazole and propylthiouracil and adjusted according to the liver function and thyroid function. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results After treatment, the levels of TB, DB, FT3, FT4 and TT3 in the control group were (51.3 ± 1.9), (26.5 ± 1.2) μmol / L, (7.92 ± 1.34) pg / ml, 0.97) ng / ml in the observation group were (21.1 ± 1.5), (8.3 ± 0.8) μmol / L, (4.14 ± 1.21) pg / ml, (2.19 ± 0.82) and The differences between the two groups were statistically significant (all P <0.05). Conclusions Hyperthyroidism with liver damage need anti-thyroid treatment on the basis of conventional hepatoprotective therapy. The prognosis is good and the pain is relieved. It is worthy of clinical promotion.